Legend Biotech (LEGN) Earnings Analysis

Legend Biotech (LEGN) next reports earnings on 2026-08-10, consensus EPS 0.0551 USD. Last quarter (2026-03-10) it beat with EPS -0.08 USD vs -0.17 USD est (+52.9%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -17.30.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does LEGN next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate0.0551 USD
Revenue estimate0.36B

LEGN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-10-0.08 USD-0.17 USD+52.9%Beat
2025-11-12-0.11 USD-0.13 USD+15.4%Beat
2025-08-11-0.34 USD-0.11346 USD-199.7%Miss
2025-03-11-0.15 USD-0.248 USD+39.5%Beat
2024-08-09-0.05 USD-0.54 USD+90.7%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

LEGN valuation and analyst view

Trailing P/E-17.30
Trailing EPS-1.3543 USD
Price / book4.49
Dividend yield0.00%
Market cap4.30B
Analyst consensusBuy (16 buy / 3 hold / 0 sell)
Avg price target56.5 USD

Related research pages

Frequently asked questions

When is Legend Biotech (LEGN)'s next earnings date?

Legend Biotech is next scheduled to report on 2026-08-10, with a consensus EPS estimate of 0.0551 USD and revenue estimate of 0.36B.

Did LEGN beat earnings last quarter?

In its 2026-03-10 report, LEGN posted EPS of -0.08 USD versus a -0.17 USD estimate — a beat of 52.9%.

What is LEGN's earnings track record?

Over the last 5 reported quarters with consensus data, LEGN beat estimates 4 times (80%).

What is LEGN's current P/E ratio and EPS?

LEGN trades at a trailing P/E of -17.30 on trailing EPS of -1.3542998565736126 USD.

What do analysts rate LEGN?

Analyst consensus is "Buy" across 19 ratings (0 strong buy, 16 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 56.5 USD.